Paul Andrew Moore - Jan 5, 2023 Form 4 Insider Report for Zymeworks Inc. (ZYME)

Role
Chief Scientific Officer
Signature
/s/ Daniel Dex, Attorney-in-Fact
Stock symbol
ZYME
Transactions as of
Jan 5, 2023
Transactions value $
$0
Form type
4
Date filed
1/6/2023, 07:00 PM
Previous filing
Jul 19, 2022
Next filing
Jan 8, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZYME Stock Option (Right to Buy) Award $0 +77.5K $0.00 77.5K Jan 5, 2023 Common Stock 77.5K $8.00 Direct F1
transaction ZYME Restricted Stock Unit Award $0 +51.5K $0.00 51.5K Jan 5, 2023 Common Stock 51.5K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.
F2 Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
F3 The RSUs vest in three equal annual installments beginning on January 5, 2024.

Remarks:

Exhibit List - Exhibit 24 - Power of Attorney. On October 13, 2022, the Issuer (formerly Zymeworks Delaware Inc., a Delaware corporation) became the successor issuer of Zymeworks BC Inc. (formerly Zymeworks Inc., a corporation continued under the Business Corporations Act (British Columbia)) pursuant to Rule 12g-3 of the Securities Exchange Act of 1934, as amended. On such date the Issuer completed a series of transactions, including a redomicile, pursuant to a statutory plan of arrangement under Section 288 of the Business Corporations Act (British Columbia), as a result of which common shares of Zymeworks BC Inc. were exchanged for either shares of common stock of the Issuer or exchangeable shares issued by Zymeworks ExchangeCo Ltd., an indirect subsidiary of the Issuer.